Abstracts
Genitourinary tumours, non-prostate
845O - Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)

https://doi.org/10.1093/annonc/mdx371Get rights and content
Under an Elsevier user license
open archive

Cited by (0)